No significant difference was observed in anti-tumor efficacy between anti-PD-1 (at 1 mg/kg) and the PA-mL7N peptide at 0.5–4 mg/kg or mL7N at 2 mg/kg. This evidence concerns the gene PDCD1 and neoplasm.